Literature DB >> 19110666

Easy sphincterotomy in patients with Billroth II gastrectomy: a new technique.

Kemal Dolay1, Aliye Soylu.   

Abstract

BACKGROUND/AIMS: ERCP and endoscopic sphincterotomy in patients with Billroth II gastrectomy are technically more difficult due to the reversed anatomy. We developed a new guidewire sphincterotome that includes two 15-mm non-isolated metal parts, one of which is located 12 cm from the distal tip and the other in the proximal end. The aim of this study was to evaluate the feasibility of and outcomes with the new sphincterotome for sphincterotomy in patients with Billroth II gastrectomy.
METHODS: Between January 2004 and March 2007, 11 patients with Billroth II gastrectomy underwent endoscopic sphincterotomy with the new guidewire sphincterotome. Procedures were initiated by deep cannulation of the bile duct with a standard catheter and guidewire sphincterotome. After cholangiography, the catheter was withdrawn with 0.5 to 1 cm of its tip outside the duodenoscope. The distal non-isolated part of the sphincterotome was placed in the papillary orifice. In order to reach the proper position, the duodenoscope's elevator was moved to the downward position, the up-down dial was turned slightly in the downward direction, and then the duodenoscope was pushed slightly forward. Finally, sphincterotomy was performed in the 6 o'clock direction.
RESULTS: Sphincterotomy with the new sphincterotome was successfully achieved in all patients without using protective pancreatic stents. Seven patients had common bile duct stones, two pancreatitis, one odditis, and another one persistent bile duct leakage. There were no sphincterotomyrelated complications or death during this study.
CONCLUSIONS: In this pilot study, endoscopic sphincterotomy with a new guidewire sphincterotome in patients with Billroth II gastrectomy was found to be clinically successful, concise, easy to perform, efficient, and reliable. However, further large comparative studies are needed for a definite conclusion.

Entities:  

Mesh:

Year:  2008        PMID: 19110666

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  6 in total

1.  Sphincterotomy by triple lumen needle knife using guide wire in patients with Billroth II gastrectomy.

Authors:  Su Bum Park; Hyung Wook Kim; Dae Hwan Kang; Cheol Woong Choi; Ki Tae Yoon; Mong Cho; Byeong Jun Song
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Efficacy and safety of the rotatable sphincterotome during ERCP in patients with prior Billroth II gastrectomy (with videos).

Authors:  Feng Zhu; Yaping Guan; Jing Wang
Journal:  Surg Endosc       Date:  2021-03-17       Impact factor: 4.584

3.  Forward-viewing endoscope for ERCP in patients with Billroth II gastrectomy: a systematic review and meta-analysis.

Authors:  Tae Young Park; Chang Seok Bang; Sang Hyeon Choi; Young Joo Yang; Suk Pyo Shin; Ki Tae Suk; Gwang Ho Baik; Dong Joon Kim; Jai Hoon Yoon
Journal:  Surg Endosc       Date:  2018-05-17       Impact factor: 4.584

4.  Utility of the Anterior Oblique-Viewing Endoscope and the Double-Balloon Enteroscope for Endoscopic Retrograde Cholangiopancreatography in Patients with Billroth II Gastrectomy.

Authors:  Manabu Sen-Yo; Seiji Kaino; Shigeyuki Suenaga; Toshiyuki Uekitani; Kanako Yoshida; Megumi Harano; Isao Sakaida
Journal:  Gastroenterol Res Pract       Date:  2012-09-30       Impact factor: 2.260

5.  Endoscopic papillary large balloon dilation for the retrieval of bile duct stones after prior Billroth II gastrectomy.

Authors:  Kook Hyun Kim; Tae-Nyeun Kim
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485

6.  Ursodeoxycholic acid combined with percutaneous transhepatic balloon dilation for management of gallstones after elimination of common bile duct stones.

Authors:  Hai-Yang Chang; Chang-Jun Wang; Bin Liu; Yong-Zheng Wang; Wu-Jie Wang; Wei Wang; Dong Li; Yu-Liang Li
Journal:  World J Gastroenterol       Date:  2018-10-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.